Abbott secures CE Mark for dual glucose and ketone monitoring sensor
Medical Device Network reports that Abbott has received CE Mark approval for Libre Duo and Libre Duo 10 Day, the world’s first continuous monitoring systems capable of measuring both glucose and ketone levels using a single wearable sensor. The technology is designed to provide real-time visibility into rising ketone levels alongside glucose monitoring, helping people with diabetes identify the risk of diabetic ketoacidosis (DKA) earlier and potentially avoid serious medical emergencies.
The approval highlights the continued evolution of wearable biosensor technologies beyond traditional glucose monitoring and further strengthens Abbott’s position within the rapidly growing digital diabetes care market. Integrated monitoring platforms like Libre Duo also demonstrate how connected wearable devices are increasingly supporting more proactive, preventative and data-driven approaches to chronic disease management.
🔗 Read the full article on Medical Device Network: Abbott receives CE Mark for Libre Duo continuous glucose and ketone sensor
Credit for images and content: Medical Device Network
____________________________________________________________________________________________________________________________________________________________________________________________________
Cure Talent is a recruitment agency dedicated to the medical technology industry. Whether you are looking for a new role in the medical device sector or you’re an innovative medical device, digital health, or biotech company looking for staff, get in touch with the team today and explore how Cure Talent can help!